NextGen Scientific is a life sciences company that has taken a strategic investment position in Ionics Life Sciences and its subsidiaries to build a diversified healthcare platform. Its portfolio exposure includes Genzada Pharmaceuticals USA, which has two clinical-stage drug candidates—GZ17-6.02 (an oral compound in a metastatic prostate cancer study at Virginia Commonwealth University) and GZ21T (a topical therapy expected to enter a Phase 1b/2a trial in Q1 2026 in Sweden and the Netherlands). The company also participates in Hyatt Life Sciences, a revenue-generating nutraceutical and botanical sciences business. NextGen plans to use capital to support clinical and preclinical advancement, drug manufacturing, and targeted marketing for its supplement portfolio. The company emphasizes creating long-term value through clinical innovation alongside active revenue streams.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2026